ArticleResearch square2025
Structural Neuroimaging Markers of Dementia: Insights from ROC Curve Analysis.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Alzheimer's disease and related dementias (ADRD) are growing public health concerns. Early and accurate differentiation between cognitively normal (NL), mild cognitive impairment (MCI), and dementia is essential for timely intervention. Structural MRI biomarkers-such as grey matter volume (GMV), white matter volume (WMV), white matter hyperintensity volume (WMH), AD signature (a meta-region of interest), and hippocampal occupancy score (HOC)-offer promise for objectively staging cognitive decline. Objective: This study aimed to evaluate the diagnostic utility of MRI-derived neuroimaging measures using receiver operating characteristic (ROC) curve analysis to identify optimal thresholds for distinguishing between NL, MCI, and dementia. Methods: Data were collected from 466 participants at the KU Alzheimer's Disease Research Center between 2010 and 2025. T1-weighted MRI scans were preprocessed using SPM12 and VBM12. Statistical analyses included ANOVA, Tukey's HSD, Welch's t-tests, and ROC analyses. Youden's J statistic was used to determine optimal cut-points, and multivariate models assessed combined biomarker performance. Results: Significant differences were found across diagnostic groups for GMV, WMH, AD signature, and HOC. ROC analysis for Demented vs the control group (NL) showed GMV had an AUC of 0.674 [0.6164, 0.7325], WMH an AUC of 0.700 [0.6454, 0.7539], AD signature an AUC of 0.829 [0.780, 0.8761], and HOC the highest individual performance with an AUC of 0.878 [0.8426, 0.9144]. Further ROC analysis confirmed AD signature and HOC as the most effective biomarkers (AUCs = 0.78 and 0.81) for distinguishing MCI/demented from NL. In MCI vs. demented comparisons, AD signature and HOC biomarkers had AUCs of 0.70 and 0.73, respectively. Conclusions: MRI-derived biomarkers, particularly AD signature and HOC, show strong potential for differentiating cognitive impairment stages. ROC-based thresholds offer clinically actionable metrics that can improve diagnostic precision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.